Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Clinical Oncology Clear all
Not yet recruiting Phase 1 Interventional

A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

NCT07579208
View directory record Official record
Conditions
Phase 1, NK Cell, IL13Ra, EGFRvIII, Chimera Antigen Receptor (CAR), NR3C1, Recurrent Glioblastoma
Interventions
NK Cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 22, 2026, 6:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer

NCT00645333
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
MK-0752, Docetaxel, Pegfilgrastim
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Jul 22, 2026, 6:01 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

NCT02401347
View directory record Official record
Conditions
Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer
Interventions
Talazoparib Tosylate
Drug
Lead sponsor
Melinda Telli
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jul 22, 2026, 6:01 AM EDT
Recruiting Phase 3 Interventional

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

NCT04852887
View directory record Official record
Conditions
Stage I Breast Cancer
Interventions
Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Other · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
50 Years to 70 Years
Enrollment
1,670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2041
U.S. locations
812
States / cities
Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 22, 2026, 6:01 AM EDT
Completed Phase 2 Interventional

Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome

NCT00023621
View directory record Official record
Conditions
Non-melanomatous Skin Cancer
Interventions
celecoxib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Jul 22, 2026, 6:01 AM EDT
Terminated Phase 3 Interventional

CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts

NCT03085004
View directory record Official record
Conditions
Pancreatic Cyst, EUS-FNA
Interventions
Ethanol, Normal saline, Paclitaxel + Gemcitabine admixture
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 22, 2026, 6:01 AM EDT
Not yet recruiting No phase listed Observational

Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials

NCT06029465
View directory record Official record
Conditions
Rhabdomyosarcoma
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Jul 22, 2026, 6:01 AM EDT
Withdrawn Phase 1 Interventional

Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy

NCT05796271
View directory record Official record
Conditions
Lymphoma, B-Cell
Interventions
R-Chop and Roflumilast
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Jul 22, 2026, 6:01 AM EDT
Recruiting Phase 1 Interventional

Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

NCT07137871
View directory record Official record
Conditions
Breast Cancer Metastatic
Interventions
Avasopasem
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jul 22, 2026, 6:01 AM EDT
Terminated No phase listed Observational

The Utility of Time Segmental Withdrawal During Screening Colonoscopy for Increasing Adenoma Detection Rate.

NCT02538406
View directory record Official record
Conditions
Adenomatous Polyp of Colon
Interventions
Segmental withdrawal
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Jul 22, 2026, 6:01 AM EDT
Completed Phase 1 Interventional

Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer

NCT01668849
View directory record Official record
Conditions
Head and Neck Cancer, Oral Mucositis
Interventions
Grape extract, Lortab, Fentanyl patch, mouthwash
Dietary Supplement · Drug
Lead sponsor
University of Louisville
Other
Eligibility
20 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Jul 22, 2026, 6:01 AM EDT
Completed No phase listed Observational

SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial

NCT00002900
View directory record Official record
Conditions
Breast Cancer, Cardiac Toxicity
Interventions
management of therapy complications
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
105
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Jul 22, 2026, 6:01 AM EDT
Completed Not applicable Interventional

STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA

NCT03988309
View directory record Official record
Conditions
Hematuria, Urothelial Carcinoma
Interventions
Cxbladder
Diagnostic Test
Lead sponsor
Pacific Edge Limited
Industry
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Winter Garden, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Jul 22, 2026, 6:01 AM EDT
Recruiting Phase 2 Interventional

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

NCT03606967
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Computed Tomography, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Nab-paclitaxel, Personalized Synthetic Long Peptide Vaccine, Poly ICLC, Sacituzumab Govitecan, Tremelimumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
30
States / cities
Orange, California • Sacramento, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 6:01 AM EDT
Recruiting Not applicable Interventional

An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study

NCT06855706
View directory record Official record
Conditions
Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
Interventions
Behavioral Intervention, Best Practice, Biospecimen Collection, Electronic Health Record Review, Exercise Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Supportive Care
Behavioral · Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Jul 22, 2026, 6:01 AM EDT
Completed Phase 3 Interventional

Nutrition Intervention in Treating Women With Breast Cancer

NCT00002564
View directory record Official record
Conditions
Breast Cancer
Interventions
educational intervention, therapeutic dietary intervention
Other · Procedure
Lead sponsor
Institute for Cancer Prevention (IFCP)
Other
Eligibility
48 Years to 78 Years · Female only
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2013 · Synced Jul 22, 2026, 6:01 AM EDT
Recruiting Phase 1 Interventional

Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation

NCT07076498
View directory record Official record
Conditions
Glioma
Interventions
M032
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
36 Months and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 22, 2026, 6:01 AM EDT
Completed Not applicable Interventional Results available

Margin-Based Vs. Robust Photon Radiotherapy Planning in IMRT of HN-SQCC

NCT03552965
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Robust Radiotherapy planning, Margin-Based Radiotherapy planning
Other
Lead sponsor
University of Arkansas
Other
Eligibility
21 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Jul 22, 2026, 6:01 AM EDT
Completed Phase 1 Interventional

Pyroxamide in Treating Patients With Advanced Cancer

NCT00042900
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pyroxamide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Jul 22, 2026, 6:01 AM EDT
Not listed Phase 3 Interventional

T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum

NCT00002811
View directory record Official record
Conditions
Precancerous Condition
Interventions
liposomal T4N5 lotion
Drug
Lead sponsor
Applied Genetics
Industry
Eligibility
2 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
7
States / cities
Miami Beach, Florida • Ann Arbor, Michigan • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Jul 22, 2026, 6:01 AM EDT
Completed Phase 1 Interventional

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

NCT03022409
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Ceralasertib, Olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Jul 22, 2026, 6:01 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

EXoPERT EMERALD Clinical Study

NCT07186296
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer
Interventions
EXoPred
Diagnostic Test
Lead sponsor
EXoPERT
Industry
Eligibility
45 Years and older
Enrollment
1,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
9
States / cities
Long Beach, California • Los Angeles, California • Honolulu, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 6:01 AM EDT
Completed Phase 1 Interventional

A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers

NCT02467361
View directory record Official record
Conditions
Cancer
Interventions
BBI608, Ipilimumab, Nivolumab, Pembrolizumab
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
8
States / cities
Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Jul 22, 2026, 6:01 AM EDT
Completed Phase 3 Interventional Results available

FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer

NCT01721954
View directory record Official record
Conditions
Colorectal Cancer Metastatic
Interventions
FOLFOX6m, SIR-Spheres microspheres
Drug · Device
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
18
States / cities
Duarte, California • Orlando, Florida • Pembroke Pines, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Jul 22, 2026, 6:01 AM EDT